Alzheimer's disease research and treatments

This study investigates how the CD33 SNP rs12459419 affects microglial gene regulation and Alzheimer's disease risk by analyzing multiple genomic datasets.

This study identifies L-fucose as a monosaccharide neuromodulator that enhances synaptic function and mitigates Alzheimer's disease symptoms in mice.

The paper identifies RNA-binding proteins interacting with tau's repeat domain using proximity labeling, showing their enrichment in Alzheimer's and tauopathies.

This study investigates the protective effects of the APOE CC mutation against Aβ, tau, and α-synuclein pathologies in mouse models of neurodegenerative diseases.

This study investigates the effect of the APPA673T mutation on amyloid-β plaque burden in 5xFAD mice, finding a significant reduction in plaque size but not in soluble Aβ levels.

The paper identifies cell type-specific gene modules associated with Alzheimer's Disease traits using snRNASeq data from human brain tissues.

This study identifies a novel GSK-3β-eIF2Bε-BACE1 axis that links stress response dysregulation to amyloidogenesis in Alzheimer's disease, independent of canonical eIF2 phosphorylation.

This study shows that maternal high-fat diet during lactation accelerates tauopathy in THY-Tau22 mice, with sex-dependent effects where males are more affected earlier than females.

This study identifies Praja1 as an E3 ligase that ubiquitinates and degrades Tau, a key protein in tauopathies, and shows evolutionary conservation of this interaction.

This study shows that AHA1 regulates Aβ production by modulating APP expression and γ-secretase assembly, suggesting it as a therapeutic target for Alzheimer's disease.

This study shows that tau seeding in neurons occurs via transient endolysosomal perforations that remain confined within endolysosomes and require PIKfyve activity.

PRISM-ML integrates multi-omics and EHR data to identify drug repurposing opportunities in Alzheimer's disease by analyzing molecular heterogeneity and predicting therapeutic targets.

The paper identifies six CSF proteomic subtypes in Alzheimer's disease, linking BBB dysfunction to reduced tau and synaptic biomarkers, particularly in African Americans and men.

This study shows that deleting ADAP1/CentA1 in Alzheimer's disease mice reduces cognitive impairment and neuropathological features, with transcriptome analysis identifying Bid as a key mediator.

The paper compares proteomic profiles of PBMCs from male and female Alzheimer's patients and controls to identify sex-specific differences in disease mechanisms.

The paper analyzes the transcriptomic landscape of the human locus coeruleus in relation to Alzheimer's disease risk factors and neuromelanin content using spatially-resolved transcriptomics.

The paper examines sex-specific gene expression associations with Alzheimer's disease neuropathology and cognitive performance using bulk transcriptomic data from 767 individuals.

This study shows that tau-induced glycolytic reprogramming in Drosophila neurons accelerates aging and causes lethality, indicating glycolysis drives rather than protects against tauopathy.

This paper introduces a dual inhibitor targeting G9a and GSK-3β for Alzheimer's disease, showing improved memory and synaptic function in a mouse model.

This study shows tau proteins from Alzheimer's and CTE folds catalyze Aβ42 aggregation in a fold-specific manner, increasing toxicity and offering new therapeutic insights.

This study shows that DNA damage-induced epigenetic changes in an Alzheimer's mouse model lead to cognitive deficits and altered amyloid pathology.

This study investigates the effects of thermal cycling-stimulation via nasal inhalation on cognitive deficits in mice with Aβ25-35-induced Alzheimer's disease, finding improvements in cognitive performance and reduced Aβ accumulation.

This study shows that adolescent intermittent ethanol increases Aβ levels in the dorsal hippocampus of aged female TgF344-AD rats, suggesting early-life ethanol exposure exacerbates Aβ pathology with age.

This study shows that astrocyte p75NTR regulates cholesterol metabolism, reducing Aβ burden and cognitive impairment in Alzheimer's Disease.

This paper reviews and analyzes 359 studies on β-amyloid toxicity in SH-SY5Y cells, finding that toxicity depends on Aβ concentration, exposure time, and aggregation state, not cell differentiation.

This study uses bulk RNA-seq to analyze transcriptional changes in the middle temporal gyrus across Alzheimer's disease and aging, identifying distinct gene expression patterns and pathways associated with each condition.

The paper identifies molecular programs coordinated with NPTX2 that distinguish cognitive resilience in AD pathology from non-pathological cognition and AD.

The paper develops a 3D brain assembloid model to study Alzheimer's disease progression and identifies IGFBP pathways as therapeutic targets in APOE4 carriers.

This study shows that inhibiting the CGRP receptor reduces AD pathology by reprogramming lipid metabolism via the HDAC11/LXRβ/ABCA1 signaling pathway in both human and mouse models.

This study shows that tau filament seeding capacity depends on both core structure and phosphorylation in the fuzzy coat, with phospho-mimetic residues restoring activity in modified tau.